贝伐单抗在25G微切口玻璃体切除术后预防早期术后出血中的作用

Role of bevacizumab in the prevention of early postoperative haemorrhage after 25-gauge microincision vitrectomy surgery.

作者信息

Sultan Zaheer, Rizvi Syed Fawad, Qureshi Faisal Murtaza, Mahmood Syed Asaad

机构信息

Dr. Zaheer Sultan, FCPS. LRBT Free Base Eye Hospital, Korangi 2 ½, Karachi, Pakistan.

Dr. Syed Fawad Rizvi, FCPS. LRBT Free Base Eye Hospital, Korangi 2 ½, Karachi, Pakistan.

出版信息

Pak J Med Sci. 2016 Sep-Oct;32(5):1184-1187. doi: 10.12669/pjms.325.10362.

DOI:10.12669/pjms.325.10362

PMID:27882018

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5103130/

Abstract

OBJECTIVE

To evaluate the effect of preoperative intravitreal bevacizumab injection on the incidence of postoperative haemorrhage and visual prognosis, in patients undergoing 25-gauge micro incision vitrectomy surgery (MIVS) for diabetic vitreous haemorrhage.

METHODS

One hundred and twenty two eyes of 122 patients of diabetic retinopathy of both genders and aged over 18 years, who presented with non-resolving vitreous haemorrhage were enrolled for this study. All patients received an intravitreal injection of 1.25 mg/0.05 mL bevacizumab (Avastin) which was followed one week later by 25-gauge sutureless micro incision vitrectomy surgery. Main outcomes measured were best corrected visual acuity (BCVA) assessed with logMAR and post-operative vitreous haemorrhage. Follow ups were up to six months post-operatively. IBM SPSS 21 was used for data analysis.

RESULT

A total of 122 patients were included; 78 (63.9%) males and 44 (36.1%) females. Mean age at the time of surgery was 51.4 ± 13.66 years. The mean preoperative BCVA was 1.64 ± 0.427 logMAR which improved to 0.57 ± 0.253 logMAR at 12 months post-operatively (p-value < 0.001). Recurrent vitreous haemorrhage was seen in four patients (3.28%). one1 week before 25-gauge vitrectomy helps to reduce the incidence of early post-vitrectomy haemorrhage in diabetic patients.

摘要

目的

评估术前玻璃体内注射贝伐单抗对糖尿病性玻璃体积血患者行25G微切口玻璃体切除术（MIVS）后出血发生率及视力预后的影响。

方法

纳入122例年龄超过18岁、患有糖尿病性视网膜病变且玻璃体积血不吸收的患者的122只眼。所有患者均接受玻璃体内注射1.25mg/0.05mL贝伐单抗（阿瓦斯汀），1周后行25G无缝合微切口玻璃体切除术。主要观察指标为采用最小分辨角对数（logMAR）评估的最佳矫正视力（BCVA）和术后玻璃体积血情况。随访至术后6个月。采用IBM SPSS 21进行数据分析。

结果

共纳入122例患者，其中男性78例（63.9%），女性44例（36.1%）。手术时的平均年龄为51.4±13.66岁。术前平均BCVA为1.64±0.427 logMAR，术后12个月时提高至0.57±0.253 logMAR（p值<0.001）。4例患者（3.28%）出现复发性玻璃体积血。25G玻璃体切除术1周前注射有助于降低糖尿病患者玻璃体切除术后早期出血的发生率。